EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC

Qi Peng, Yuanyuan Xu, Xinsheng Yao iD

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2024-009376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Qi Peng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Zunyi Medical University, Zunyi, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Tumor Microenvironment, Receptors, Antigen, T-Cell. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guizhou Provincial High Level Innovative Talent Fund, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The intricate origins, subsets, and characteristics of TCR (T Cell Receptor) s, along with the mechanisms underpinning the antitumor response of tumor-infiltrating T lymphocytes within the tumor microenvironment (TME) remain enigmatic. Recently, the advent of single-cell RNA+TCR-sequencing (scRNA+TCR seq) has revolutionized TME analysis, providing unprecedented insight into the origins, cell subsets, TCR CDR3 compositions, and the expression patterns of response/depletion factors within individual tumor-infiltrating T lymphocytes. Our analysis of the shared scRNA+TCR seq dataset revealed a substantial presence of dual TCR T cells, characterized by clonal hyperplasia and remarkable migratory prowess across various tissues, including blood, normal, peritumoral, and tumor tissues in non-small cell lung cancer patients. Notably, dual TCR CD8+T cells predominantly fell within the CXCL13+subset, displaying potent antitumor activity and a strong preference for tumor tissue residency. Conversely, dual TCR CD4+T cells were predominantly classified as CD5+ or LMNA+subsets, exhibiting a more even distribution across diverse tissue types. By harnessing scRNA+TCR seq and other cutting-edge technologies, we can delve deeper into the effects and mechanisms that regulate the antitumor response or tolerance of dual TCR T cells. This innovative approach holds immense promise in offering fresh perspectives and avenues for advancing research on TIL (Tumor infiltrating lymphocyte)s within the TME.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsTumor MicroenvironmentReceptors, Antigen, T-CellHumansLymphocytes, Tumor-InfiltratingSingle-Cell Analysis

Stichwörter der Autor:innen

Lung CancerT cell Receptor - TCRTumor infiltrating lymphocyte - TILTumor microenvironment - TME

Substanzen

Receptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Immunology, Zunyi Medical University, Zunyi, China.
  • Department of Immunology, Zunyi Medical University, Zunyi, China immunology@126.com.

ORCID-Profile: Xinsheng Yao

Förderung

  • Guizhou Provincial High Level Innovative Talent Fund
  • National Natural Science Foundation of China

Zitieren

APA

Peng, Q., Xu, Y., & Yao, X. (2024). scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009376

Vancouver

Peng Q, Xu Y, Yao X. scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009376

BibTeX
@article{Peng2024,
  author = {Peng, Qi and Xu, Yuanyuan and Yao, Xinsheng},
  title = {scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-009376}
}
Kostenlos starten →